Plasma Cell Neoplasms - Molecular Testing
Working Group Charter
Plasma Cell Neoplasms - Molecular Testing
Work Product Category
Manuscript or Publication
Specific Aims for the Work Product
We propose focusing first on laboratory practices to help the community understand the technical issues when sequencing plasma cell neoplasms.
We aim to do so by reviewing laboratory molecular practices, sharing suggested preanalytical protocols, discussing enrichment practices, appropriate sample types, and common post-analytical findings, and offering best practices for a variety of techniques (e.g., plasma cell enrichment for genome or NGS panel testing, no plasma cell enrichment with high-sensitivity sequencing, DNA only sequencing, and DNA and RNA sequencing).
This Working Group is focused on developing evidence-based guidelines and standardized practices for the clinical implementation of next-generation sequencing (NGS) in plasma cell neoplasms (PCN). Our goals include addressing technical methodologies, clinical utility, and interpretation standards across various disease stages.
The clinical genomics community currently does not have any guidance, recommendations, or comprehensive information about implementing or performing next generation sequencing on patients with plasma cell neoplasms (PCN). This Working Group aims to fill this gap.
Working Group Members
Celeste Eno
Cedars-Sinai Medical Center
Linda B. Baughn
Mayo Clinic
Patrick R. Gonzales
University of Kansas Medical Center
Tingwei Guo
Fox Chase Cancer Center
Angela M. Lager
University of Chicago
Xinyan Lu
Northwestern University Feinberg School of Medicine
Trevor Pugh
University of Toronto
Jennie Thurston
Atrium Health
Jian Zhao
University of Utah and ARUP Laboratories
Celeste Eno